ASH 2020 | Non-invasive monitoring of smoldering multiple myeloma
Bruno Paiva, PhD, University of Navarra, Pamplona, Spain, discusses the prospect of a minimally invasive technique for continual monitoring smoldering multiple myeloma (SMM). Preliminary results of the iMMunocell study show circulating tumor cells (CTC) taken from the peripheral blood, as opposed to invasive bone marrow aspirates can provide clinical benefit, where CTC counts are significantly correlated to progressive disease. Dr Paiva goes on to discuss how this non-invasive technique could potentially complement the 20/20/20 criteria for real-time monitoring of key immune cell types associated with malignant transformation and in turn, can identify patients at risk of disease progression into active multiple myeloma (MM). This interview took place during the 62nd American Society of Hematology (ASH) 2020 Annual Meeting and Exposition.
